UNSPSC 51172430: Belladonna/dehydrocholic acid/lipase/ox bile/pancreatin/pepsin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA500. This VA Drug Class (GA500) classifies this compound as belonging to the group DIGESTANTS.

UNSPSC 51172430 Belladonna/dehydrocholic acid/lipase/ox bile/pancreatin/pepsin is a Commodity code for pharmaceutical formulations combining digestive enzymes and bile salts, yet the recent state and local contracting activity under this code shows no alignment with the nominal pharmaceutical scope. The single recent opportunity tagged to this code—Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services—involves laboratory-based drug screening and confirmation testing with no connection to the digestive-system medications the code nominally describes. This mismatch suggests either a data-entry error in code assignment or a fundamental divergence between the UNSPSC taxonomy and how the issuing jurisdiction classified the procurement.

The Collin County opportunity, posted September 25, 2026 with a response deadline of July 23, 2026, requests proposals to staff two drug-testing collection sites in Plano and McKinney, operate an automated notification system for randomized testing, perform immunoassay screening with LC/MS/MS or GC/MS confirmation, and offer alternative testing methodologies including oral fluid and hair analysis. The estimated contract value is $600,000 over an initial two-year term with three optional one-year renewal periods. Vendors must hold lab certification from SAMHSA, TX DPS, or CAP and submit pricing on a per-test basis with three service models (screening only, confirmation after screening, or automatic confirmation of positives). Evaluation scoring weights vendor understanding (30 points), firm qualifications (25 points), client references (15 points), and cost (30 points), with optional Phase 2 demonstrations and interviews. Given the absence of additional opportunities and the clear code-to-scope mismatch in the single record, this code shows little relevant recent activity for vendors in the digestive-pharmaceutical space.